A Answers (1)
In 1996, COP-1 was released as Copaxone. This injectable drug was engineered to desensitize the immune system. Although no one knows exactly how it works, it is believed to alter the basic mechanism of T-cell activation. Studies show it reduces the frequency of multiple sclerosis (MS) relapses by a third, reduces the number of MS lesions seen on magnetic resonance imaging (MRI) - especially new ones - and may reduce the number of new lesions that evolve into "black holes," areas that cause permanent damage to nerve fibers, called axons.
Important: This content reflects information from various individuals and organizations and may offer alternative or opposing points of view. It should not be used for medical advice, diagnosis or treatment. As always, you should consult with your healthcare provider about your specific health needs.